Cas:55286-97-0 1,2,3,6-TETRA-O-ACETYL-α-D-GLUCOPYRANOSE manufacturer & supplier

We serve Chemical Name:1,2,3,6-TETRA-O-ACETYL-α-D-GLUCOPYRANOSE CAS:55286-97-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1,2,3,6-TETRA-O-ACETYL-α-D-GLUCOPYRANOSE

Chemical Name:1,2,3,6-TETRA-O-ACETYL-α-D-GLUCOPYRANOSE
CAS.NO:55286-97-0
Synonyms:1,2,3,6-Tetra-O-acetyl-a-D-glucopyranose
Molecular Formula:C14H20O10
Molecular Weight:348.30300
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:433.823ºC at 760 mmHg
Density:1.339 g/cm3
Index of Refraction:
PSA:134.66000
Exact Mass:348.10600
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1,2,3,6-Tetra-O-acetyl-a-D-glucopyranose chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2,3,6-Tetra-O-acetyl-a-D-glucopyranose physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,2,3,6-Tetra-O-acetyl-a-D-glucopyranose Use and application,1,2,3,6-Tetra-O-acetyl-a-D-glucopyranose technical grade,usp/ep/jp grade.


Related News: Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs. 1,2,3,6-TETRA-O-ACETYL-α-D-GLUCOPYRANOSE manufacturer Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs. 1,2,3,6-TETRA-O-ACETYL-α-D-GLUCOPYRANOSE supplier Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK. 1,2,3,6-TETRA-O-ACETYL-α-D-GLUCOPYRANOSE vendor Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said. 1,2,3,6-TETRA-O-ACETYL-α-D-GLUCOPYRANOSE factory From the perspective of product structure, the varieties of these enterprises are mainly concentrated in vitamins, antipyretics and analgesics, antibiotics and corticosteroids (ie bulk drug substances).